162 related articles for article (PubMed ID: 36866691)
1. Mammographic Density Reduction is Associated to the Prognosis in Asian Breast Cancer Patients Receiving Hormone Therapy.
Shia WC; Lin LS; Wu HK; Chen CJ; Chen DR
Cancer Control; 2023; 30():10732748231160991. PubMed ID: 36866691
[TBL] [Abstract][Full Text] [Related]
2. Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.
Atakpa EC; Thorat MA; Cuzick J; Brentnall AR
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013091. PubMed ID: 34697802
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
[TBL] [Abstract][Full Text] [Related]
4. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.
Li J; Humphreys K; Eriksson L; Edgren G; Czene K; Hall P
J Clin Oncol; 2013 Jun; 31(18):2249-56. PubMed ID: 23610119
[TBL] [Abstract][Full Text] [Related]
5. Mammographic Density Reduction as a Prognostic Marker for Postmenopausal Breast Cancer: Results Using a Joint Longitudinal-Survival Modeling Approach.
Andersson TM; Crowther MJ; Czene K; Hall P; Humphreys K
Am J Epidemiol; 2017 Nov; 186(9):1065-1073. PubMed ID: 28633324
[TBL] [Abstract][Full Text] [Related]
6. Possible influence of mammographic density on local and locoregional recurrence of breast cancer.
Eriksson L; Czene K; Rosenberg L; Humphreys K; Hall P
Breast Cancer Res; 2013; 15(4):R56. PubMed ID: 23844592
[TBL] [Abstract][Full Text] [Related]
7. High mammographic breast density predicts locoregional recurrence after modified radical mastectomy for invasive breast cancer: a case-control study.
Huang YS; Chen JL; Huang CS; Kuo SH; Jaw FS; Tseng YH; Ko WC; Chang YC
Breast Cancer Res; 2016 Dec; 18(1):120. PubMed ID: 27906044
[TBL] [Abstract][Full Text] [Related]
8. Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery.
Cil T; Fishell E; Hanna W; Sun P; Rawlinson E; Narod SA; McCready DR
Cancer; 2009 Dec; 115(24):5780-7. PubMed ID: 19902459
[TBL] [Abstract][Full Text] [Related]
9. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer.
Kim J; Han W; Moon HG; Ahn S; Shin HC; You JM; Han SW; Im SA; Kim TY; Koo H; Chang J; Cho N; Moon W; Noh DY
Breast Cancer Res; 2012 Jul; 14(4):R102. PubMed ID: 22770227
[TBL] [Abstract][Full Text] [Related]
10. Mammographic density as a predictor of breast cancer survival: the Multiethnic Cohort.
Maskarinec G; Pagano IS; Little MA; Conroy SM; Park SY; Kolonel LN
Breast Cancer Res; 2013 Jan; 15(1):R7. PubMed ID: 23339436
[TBL] [Abstract][Full Text] [Related]
11. Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer.
Kim WH; Cho N; Kim YS; Yi A
Eur Radiol; 2018 Aug; 28(8):3176-3184. PubMed ID: 29626240
[TBL] [Abstract][Full Text] [Related]
12. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
[TBL] [Abstract][Full Text] [Related]
13. MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
Lo Gullo R; Daimiel I; Rossi Saccarelli C; Bitencourt A; Sevilimedu V; Martinez DF; Jochelson MS; Morris EA; Reiner JS; Pinker K
Breast Cancer Res; 2020 Aug; 22(1):93. PubMed ID: 32819432
[TBL] [Abstract][Full Text] [Related]
14. Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.
Brentnall AR; Warren R; Harkness EF; Astley SM; Wiseman J; Fox J; Fox L; Eriksson M; Hall P; Cuzick J; Evans DG; Howell A
Breast Cancer Res; 2020 Sep; 22(1):101. PubMed ID: 32993747
[TBL] [Abstract][Full Text] [Related]
15. Digital versus screen-film mammography: impact of mammographic density and hormone therapy on breast cancer detection.
Chiarelli AM; Prummel MV; Muradali D; Shumak RS; Majpruz V; Brown P; Jiang H; Done SJ; Yaffe MJ
Breast Cancer Res Treat; 2015 Nov; 154(2):377-87. PubMed ID: 26518019
[TBL] [Abstract][Full Text] [Related]
16. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
17. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
18. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
van Nes JG; Beex LV; Seynaeve C; Putter H; Sramek A; Lardenoije S; Duijm-de Carpentier M; Van Rongen I; Nortier JW; Zonderland HM; van de Velde CJ
Acta Oncol; 2015 Mar; 54(3):349-60. PubMed ID: 25383451
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and tumor characteristics of interval cancers by mammographic density.
Holm J; Humphreys K; Li J; Ploner A; Cheddad A; Eriksson M; Törnberg S; Hall P; Czene K
J Clin Oncol; 2015 Mar; 33(9):1030-7. PubMed ID: 25646195
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
